Calcitonin News and Research

RSS

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.

Specialized immune cells bridge the nervous and immune systems

A collaborative team led by Professor Jie Zhou at Tianjin Medical University School of Basic Medicine and Professor Qiang Liu at Tianjin Medical University General Hospital published a comprehensive review in Volume 2 of the journal Immunity & Inflammation on September 8, 2026.

25 Sep 2026

A personalized elimination diet changed the gut microbiome in people with migraine

In a 12-week randomized, sham-controlled trial of 98 adults with migraine, eliminating IgG-positive foods altered gut microbial composition and produced a greater reduction in serum zonulin than a sham elimination diet. The microbial changes were associated with previously reported reductions in CGRP and IL-6 and improvements in migraine and sleep, although the authors emphasized that these mechanistic links remain exploratory.

31 Aug 2026

Researchers identify molecular targets to treat painful nerve neuromas

Human peripheral nerves have a remarkable ability to regenerate after damage. However, when re-growing axons fail to meet their target organ, they can transform into painful neuromas.

11 Aug 2026

Sensory nerve signals found to block lung cancer immunotherapy

Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system's response to lung cancer.

19 May 2026

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

Immune cells use neurotransmitters to regulate health and disease

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, 2026, in Immunity & Inflammation, provides a timely and authoritative review of how innate and adaptive immune cells-including macrophages, dendritic cells, natural killer cells, T cells, and B cells-produce and respond to classic neurotransmitters.

25 Mar 2026

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Two analgesic drugs may one day be repurposed as anti-tumor therapies

Peripheral afferent neurons - nerves that send signals from all areas of the body to the central nervous system (brain and spinal cord) - are known to infiltrate and grow within malignant bone tumors called osteosarcomas, often accompanied by severe pain.

29 Oct 2025

Ketogenic diets may lower migraine frequency and medication use

This narrative review argues that the migraine brain is hypometabolic, with converging evidence of mitochondrial dysfunction, impaired glucose handling, neuroinflammation, microbiome shifts, and obesity-related pathways. It proposes ketogenic diets as a plausible preventive strategy that may reduce monthly migraine days and medication use, while emphasizing the need for larger, rigorous randomized trials and careful clinical oversight.

14 Sep 2025

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

Diabetic nerve damage weakens bones by disrupting cell communication

Diabetes affects millions worldwide, causing both nerve and metabolic complications. A recent study suggests that diabetic nerve damage may also lead to impaired bone health.

18 Jul 2025

Scientists discover pathway linking physical pain to emotional suffering

Pain isn't just a physical sensation-it also carries emotional weight. That distress, anguish, and anxiety can turn a fleeting injury into long-term suffering.

10 Jul 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

Ubrogepant relieves early migraine symptoms and may help prevent full-blown attacks

A phase 3 trial found that ubrogepant, given during the premonitory phase of migraine, improved common warning symptoms such as fatigue, light and sound sensitivity, and neck pain. These benefits were observed as early as one hour post-treatment, suggesting early intervention can reduce migraine burden.

15 May 2025